Clinical Trial Spotlight
Friday, August 22nd, 2008Research to determine the effectiveness of MBP8298 drug in delaying secondary progressive multiple sclerosis.
Clinical TrialsModulation of Inflammatory Response in Multiple Sclerosis by Altered Peptide Ligand (APL)Thursday, July 14th, 2005Silva Markovic-Plese, MD—Department of Neurology, University of North Carolina at Chapel Hill, A Summary of Rebif Clinical TrialsSaturday, September 4th, 2004Stacy Oswald, BS, MSQR Coorinator – Barrow Neurological Institute; and Timothy Vollmer, MD, Chief, Neuroimmunology Section – Division of Neurology and Director – Barrow MS and Related Diseases Clinic and Research Center, Phoenix, AZ Clinical Trial of Mitoxantrone Versus Methylprednisolone in Relapsing, Secondary MSTuesday, July 9th, 2002A double blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 Belgian patients with relapsing, secondary MS. Patients were randomized to receive 13 infusions of mitoxantrone 12 mg/m2 ( 2 8 patients) or 13 infusions of 1g of methylprednisolone (21 patients), over 32 months. Twenty-four patients completed the trial. Second Patient With MS Undergoes Schwann Cell Transplantation Surgery at YaleTuesday, July 9th, 2002A 29-year-old man with MS is the second patient to undergo transplantation surgery at Yale in an effort to repair myelin. The surgery took place in two stages on March 6–7 and the patient was discharged on March 10. The young man is the second of five patients who are scheduled to participate [...] |
|